In the last week, the U.S. market has been flat, but it has shown a 14% increase over the past year, with earnings projected to grow by 15% annually. Penny stocks may be a throwback term, yet they remain relevant for investors seeking opportunities in smaller or newer companies that could offer growth at lower price points. With strong financial foundations and solid fundamentals, these stocks can present underappreciated opportunities for those looking to uncover hidden gems in today's market landscape.
Top 10 Penny Stocks In The United States
| Name | Share Price | Market Cap | Rewards & Risks |
| Waterdrop (WDH) | $1.70 | $607.59M | ✅ 4 ⚠️ 0 View Analysis > |
| CuriosityStream (CURI) | $4.48 | $266.61M | ✅ 3 ⚠️ 3 View Analysis > |
| WM Technology (MAPS) | $0.9581 | $160.22M | ✅ 4 ⚠️ 1 View Analysis > |
| Tuniu (TOUR) | $0.9326 | $98.4M | ✅ 3 ⚠️ 2 View Analysis > |
| Safe Bulkers (SB) | $4.07 | $421.52M | ✅ 2 ⚠️ 3 View Analysis > |
| Cardno (COLD.F) | $0.1701 | $6.64M | ✅ 2 ⚠️ 4 View Analysis > |
| BAB (BABB) | $0.845 | $6.14M | ✅ 2 ⚠️ 3 View Analysis > |
| Lifetime Brands (LCUT) | $4.61 | $100.19M | ✅ 3 ⚠️ 2 View Analysis > |
| North European Oil Royalty Trust (NRT) | $4.92 | $44.85M | ✅ 2 ⚠️ 2 View Analysis > |
| Tandy Leather Factory (TLF) | $3.36 | $28.05M | ✅ 2 ⚠️ 2 View Analysis > |
Click here to see the full list of 421 stocks from our US Penny Stocks screener.
Underneath we present a selection of stocks filtered out by our screen.
Tiziana Life Sciences (TLSA)
Simply Wall St Financial Health Rating: ★★★★★★
Overview: Tiziana Life Sciences Ltd is a biotechnology company focused on developing transformative therapies for neurodegenerative and lung diseases in the United States, with a market cap of $172.77 million.
Operations: Tiziana Life Sciences Ltd has not reported any revenue segments.
Market Cap: $172.77M
Tiziana Life Sciences, a pre-revenue biotechnology firm with a market cap of US$172.77 million, is advancing its intranasal foralumab treatment for Alzheimer's and multiple sclerosis. Recent findings highlight the drug's potential to modulate immune responses and reduce brain inflammation, crucial for neurodegenerative diseases. Despite promising clinical developments and being debt-free, Tiziana faces financial challenges with a cash runway of 1.4 years if historical cash flow reductions persist. The company's high stock volatility and unprofitable status underscore the risks associated with penny stocks in this sector, although management is actively pursuing innovative therapies to address unmet medical needs.
- Click to explore a detailed breakdown of our findings in Tiziana Life Sciences' financial health report.
- Examine Tiziana Life Sciences' past performance report to understand how it has performed in prior years.
Destination XL Group (DXLG)
Simply Wall St Financial Health Rating: ★★★★★☆
Overview: Destination XL Group, Inc. operates as a specialty retailer of big and tall men's clothing and footwear in the United States, with a market cap of $70.50 million.
Operations: The company's revenue is primarily derived from its retail segment, which generated $457.06 million.
Market Cap: $70.5M
Destination XL Group, Inc., with a market cap of US$70.50 million, is navigating the challenges typical of penny stocks. Despite being unprofitable, the company has reduced its losses over five years and forecasts significant earnings growth at 56.77% annually. The absence of debt provides some financial stability; however, short-term assets fall short of covering long-term liabilities by US$28.2 million. Recent store openings highlight strategic expansion efforts despite being dropped from multiple Russell indices in June 2025 due to declining sales and recent net losses reported at US$1.94 million for Q1 2025 compared to previous profits.
- Navigate through the intricacies of Destination XL Group with our comprehensive balance sheet health report here.
- Understand Destination XL Group's earnings outlook by examining our growth report.
Clover Health Investments (CLOV)
Simply Wall St Financial Health Rating: ★★★★★☆
Overview: Clover Health Investments, Corp. offers Medicare Advantage plans in the United States and has a market cap of approximately $1.50 billion.
Operations: The company generates revenue primarily from its insurance segment, which amounted to $1.49 billion.
Market Cap: $1.5B
Clover Health Investments, Corp., with a market cap of US$1.50 billion, is characterized by its unprofitability yet demonstrates potential through strategic initiatives and financial positioning. The recent launch of a pharmacy pilot program in New Jersey underscores its commitment to leveraging technology for community-based healthcare solutions. Despite negative return on equity at -7.25%, Clover remains debt-free and has short-term assets exceeding liabilities by over US$115 million, providing some financial cushion. Its inclusion in multiple Russell indices reflects recognition within growth benchmarks, while the appointment of Joe Oldakowski as VP of Finance aims to bolster financial oversight and reporting capabilities.
- Jump into the full analysis health report here for a deeper understanding of Clover Health Investments.
- Gain insights into Clover Health Investments' future direction by reviewing our growth report.
Make It Happen
- Discover the full array of 421 US Penny Stocks right here.
- Searching for a Fresh Perspective? Trump's oil boom is here — pipelines are primed to profit. Discover the 22 US stocks riding the wave.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we're here to simplify it.
Discover if Destination XL Group might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com